K
KALA BIO
Biotech & Life Sciences · Waltham, United States · Founded 2009 · IPO 2017
Development and commercialization of therapeutics using our proprietary nanoparticle-based Mucus Penetrating Particles MoreLess
KALA BIO is a clinical-stage biopharmaceutical company that researches, develops, and commercializes therapies for rare and severe eye diseases.
The company is advancing the clinical development of KPI-012 for the treatment of Persistent Corneal Epithelial Defect (PCED), a rare disease of the cornea that can lead to vision loss. KALA BIO has hosted a Key Opinion Leader (KOL) event to discuss the potential of KPI-012 for the treatment of PCED.
To fund its operations and the clinical development of its product candidates, the company raises capital through private placements. For instance, KALA BIO has recently announced a private placement to advance the clinical development of KPI-012.
Keywords: biopharmaceutical, clinical-stage, eye diseases, rare diseases, PCED, KPI-012, cornea, therapies, vision loss, ophthalmology
Talent graph
KALA BIO's talent
Source: Dealroom Talent Intelligence.
Global footprint
Where KALA BIO has talent and traffic
team presence
Market sentiment
What the market is saying about KALA BIO
An AI-synthesized read of the highest-engagement posts about KALA BIO on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See KALA BIO on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.